Half-year Financial Report
AstraZeneca reported H1 2026 total revenue of $30.67 billion, up 9% year-over-year, driven by double-digit growth in Oncology and Rare Disease. Core EPS increased 12% to $5.21, while reported EPS rose 4% to $3.60. The company declared an interim dividend of $1.06 per share, a 3-cent increase, and reaffirmed its ambition to achieve $80 billion in total revenue by 2030. Management remains confident in the pipeline despite a disappointing outcome in the CARDIO-TTRansform trial.
Key figures
- Eps
- 5.21
- Revenue
- 30672000000
- Guidance
- $80 billion in Total Revenue by 2030
- Revenue Yoy
- 9%
- Q2 revenue
- 15384000000
- Reported eps
- 3.6
- Core eps growth
- 12%
- Interim dividend
- 1.06
- Major approvals period
- 30
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.